Imara Q2 net loss $13.2M; IMR-687 SCD trial fully enrolled; interim data Q4 2021

Enliven Therapeutics, Inc.

2022-Q2 EPS reported -$1.33

Net loss $13.2M ($0.74/share) vs $10.2M ($0.59) in Q2 2020.
Cash $66.8M at June 30; $50M July offering extends runway through 2022.
SCD Phase 2b (Ardent) enrollment complete; primary analysis Q1 2022, interim Q4 2021.
Beta-thalassemia Phase 2b (Forte) TDT cohort fully enrolled; interim data Q4 2021; NTDT half enrolled.
Developing HFpEF Phase 2 protocol; FDA interaction planned Q4 2021; Laura Williams appointed to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.